FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891032731> ?p ?o ?g. }

• W2891032731 abstract "8010 Background: The Stamina trial primarily aimed to identify the best strategy among AM, ACM, and TAM, leading to longer PFS (LBA-1, ASH, 2016). Here we report on interim, exploratory results of the association between PFS and overall survival (OS) and baseline MM response, risk category, and treatments (Rx). Methods: Pts with MM, < 71 years, < 12 mos from diagnosis were randomized to melphalan 200mg/m 2 (mel) and AHCT (AM), tandem mel AHCT (TAM), or mel AHCT and 4 cycles of RVD ((ACM). Pts received Len till progression. Pts were stratified by high risk vs. standard ( del13q, del17q, t(4;14), t(14;16), t(14;20) and hypodyploid; high β2 microglobulin). Kaplan Meier estimates of PFS and OS were performed as a function of Rx and ≥ very good partial response (VPGR including CRs) vs. < VGPR. Cox proportional hazard models explored associations between PFS or OS and risk category, Rx, and ≥ VPGR vs. < VGPR. Results: Between 6/2010-11/2013, 758 pts (AM, N = 257; ACM, N = 254; TAM, N = 247) aged 20-70 years (median 57y) were enrolled (24% high-risk). Baseline ≥VGPR responses were 45.5- 49.8%. PFS at 38 months was similar. For < VGPR, 38-mos PFS with TAM:55.8% (95%CI: 45.8%, 64.7%); ACM: 54.0% (44.7%, 62.5%); AM: 50.1% (40.6%, 58.9%); For ≥VGPR, 38-mos PFS with TAM: 57.1% (46.8%, 66.1%); ACM: 60.1% (50.1%, 68.7%); AM: 55.1% (45.1%, 64.0%). Analyzing response, risk category, and Rx revealed no association between baseline response and PFS (Baseline response < VGPR, hazard ratio (HR): 1.21,95% CI: 0.97-1.52) or OS (baseline response < VGPR, HR 1.02, 95%CI:0.70-1.48). High risk category had an adverse association for PFS (HR 1.62, 95% CI: 1.27-2.07) and OS (HR 1.51 (95% CI:1.01-2.26). Conclusions: In this analysis < VGPR at baseline was not associated with PFS or OS. High-risk had an adverse association. Whether accomplishment of CR/minimal residual disease after AM, ACM,or TAM predicts for longer PFS and OS is the subject of ongoing analysis. Clinical trial information: NCT01109004." @default.
• W2891032731 created "2018-09-27" @default.
• W2891032731 creator A5003055083 @default.
• W2891032731 creator A5004466299 @default.
• W2891032731 creator A5004913924 @default.
• W2891032731 creator A5007847102 @default.
• W2891032731 creator A5008376636 @default.
• W2891032731 creator A5023917993 @default.
• W2891032731 creator A5026151069 @default.
• W2891032731 creator A5029390145 @default.
• W2891032731 creator A5029801761 @default.
• W2891032731 creator A5035985145 @default.
• W2891032731 creator A5041561013 @default.
• W2891032731 creator A5053904944 @default.
• W2891032731 creator A5057028608 @default.
• W2891032731 creator A5058362903 @default.
• W2891032731 creator A5060449393 @default.
• W2891032731 creator A5063351800 @default.
• W2891032731 creator A5070096873 @default.
• W2891032731 creator A5071880362 @default.
• W2891032731 creator A5086815330 @default.
• W2891032731 creator A5091623158 @default.
• W2891032731 date "2017-05-20" @default.
• W2891032731 modified "2023-10-01" @default.
• W2891032731 title "Response status as predictor of survival after autologous hematopoietic cell transplant (AHCT), without or with consolidation (with bortezomib, lenalidomide (Len) and dexamethasone) and len maintenance (AM vs. ACM) versus tandem AHCT and len maintenance (TAM) for up-front treatment of patients (pts) with multiple myeloma (MM): BMT CTN0702-stamina (NCT01109004)." @default.
• W2891032731 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.8010" @default.
• W2891032731 hasPublicationYear "2017" @default.
• W2891032731 type Work @default.
• W2891032731 sameAs 2891032731 @default.
• W2891032731 citedByCount "0" @default.
• W2891032731 crossrefType "journal-article" @default.
• W2891032731 hasAuthorship W2891032731A5003055083 @default.
• W2891032731 hasAuthorship W2891032731A5004466299 @default.
• W2891032731 hasAuthorship W2891032731A5004913924 @default.
• W2891032731 hasAuthorship W2891032731A5007847102 @default.
• W2891032731 hasAuthorship W2891032731A5008376636 @default.
• W2891032731 hasAuthorship W2891032731A5023917993 @default.
• W2891032731 hasAuthorship W2891032731A5026151069 @default.
• W2891032731 hasAuthorship W2891032731A5029390145 @default.
• W2891032731 hasAuthorship W2891032731A5029801761 @default.
• W2891032731 hasAuthorship W2891032731A5035985145 @default.
• W2891032731 hasAuthorship W2891032731A5041561013 @default.
• W2891032731 hasAuthorship W2891032731A5053904944 @default.
• W2891032731 hasAuthorship W2891032731A5057028608 @default.
• W2891032731 hasAuthorship W2891032731A5058362903 @default.
• W2891032731 hasAuthorship W2891032731A5060449393 @default.
• W2891032731 hasAuthorship W2891032731A5063351800 @default.
• W2891032731 hasAuthorship W2891032731A5070096873 @default.
• W2891032731 hasAuthorship W2891032731A5071880362 @default.
• W2891032731 hasAuthorship W2891032731A5086815330 @default.
• W2891032731 hasAuthorship W2891032731A5091623158 @default.
• W2891032731 hasConcept C126322002 @default.
• W2891032731 hasConcept C143998085 @default.
• W2891032731 hasConcept C2776063141 @default.
• W2891032731 hasConcept C2776364478 @default.
• W2891032731 hasConcept C2777478702 @default.
• W2891032731 hasConcept C2780401358 @default.
• W2891032731 hasConcept C71924100 @default.
• W2891032731 hasConceptScore W2891032731C126322002 @default.
• W2891032731 hasConceptScore W2891032731C143998085 @default.
• W2891032731 hasConceptScore W2891032731C2776063141 @default.
• W2891032731 hasConceptScore W2891032731C2776364478 @default.
• W2891032731 hasConceptScore W2891032731C2777478702 @default.
• W2891032731 hasConceptScore W2891032731C2780401358 @default.
• W2891032731 hasConceptScore W2891032731C71924100 @default.
• W2891032731 hasLocation W28910327311 @default.
• W2891032731 hasOpenAccess W2891032731 @default.
• W2891032731 hasPrimaryLocation W28910327311 @default.
• W2891032731 hasRelatedWork W2249791864 @default.
• W2891032731 hasRelatedWork W2344328966 @default.
• W2891032731 hasRelatedWork W2412440205 @default.
• W2891032731 hasRelatedWork W2549271193 @default.
• W2891032731 hasRelatedWork W2563266914 @default.
• W2891032731 hasRelatedWork W2605661524 @default.
• W2891032731 hasRelatedWork W2607390287 @default.
• W2891032731 hasRelatedWork W2624131270 @default.
• W2891032731 hasRelatedWork W2746647817 @default.
• W2891032731 hasRelatedWork W2750997727 @default.
• W2891032731 hasRelatedWork W2801448674 @default.
• W2891032731 hasRelatedWork W2892218501 @default.
• W2891032731 hasRelatedWork W2895334629 @default.
• W2891032731 hasRelatedWork W2909224113 @default.
• W2891032731 hasRelatedWork W2909552152 @default.
• W2891032731 hasRelatedWork W2933609368 @default.
• W2891032731 hasRelatedWork W2987950337 @default.
• W2891032731 hasRelatedWork W3029080165 @default.
• W2891032731 hasRelatedWork W3083246189 @default.
• W2891032731 hasRelatedWork W3169674421 @default.
• W2891032731 isParatext "false" @default.
• W2891032731 isRetracted "false" @default.
• W2891032731 magId "2891032731" @default.
• W2891032731 workType "article" @default.